Table 1—

Clinical and laboratory data for participants in the Bruneck and Utah study groups with stratification in patients with severe obesity and control subjects

BruneckUtah
ControlSevere obesity
n8008311,038
Age (years)62.7 ± 11.152.8 ± 8.544.4 ± 11.4*
Sex: male/female398/402 (49.8/50.2)403/428 (48.5/51.5)193/845 (18.6/81.4)*
rs12510549: TT/TC/CC506/243/35 (64.5/31.0/4.5)519/265/33 (63.5/32.4/4.1)633/335/43 (62.6/33.1/4.3)
    MAF (%)20.020.320.8
rs6449213: TT/TC/CC517/237/30 (65.9/30.2/3.8)539/259/20 (65.9/31.7/2.4)648/319/40 (64.3/31.7/4.0)
    MAF (%)18.918.319.8
rs6855911: AA/AG/GG462/283/43 (58.6/35.9/5.5)471/304/43 (57.6/37.2/5.2)526/412/69 (52.2/40.9/6.9)
    MAF (%)23.423.827.3
rs7442295: AA/AG/GG494/257/34 (62.9/32.7/4.3)501/287/28 (61.4/35.2/3.4)595/366/49 (58.9/36.2/4.9)
    MAF (%)20.721.023.0
Uric acid (mg/dl)4.7 ± 1.35.5 ± 1.56.3 ± 1.5*
BMI (kg/m2)25.6 ± 3.827.6 ± 4.946.0 ± 7.6*
Creatinine (mg/dl)0.94 ± 0.190.92 ± 0.310.81 ± 0.22*
Total cholesterol (mg/dl)230.0 ± 42.6187.1 ± 34.0186.8 ± 36.2
LDL cholesterol (mg/dl)145.5 ± 37.9105.1 ± 27.7108.2 ± 27.6
HDL cholesterol (mg/dl)58.7 ± 16.250.1 ± 15.045.9 ± 11.0*
Triglycerides (mg/dl) (25th, 50th, 75th percentile)131.7 ± 71.9 (81, 111, 158)156 ± 105 (86, 121, 169)186 ± 106 (164, 119, 223)*
Systolic blood pressure (mmHg)148.3 ± 20.7121.5 ± 16.7127.3 ± 18.5*
Diastolic blood pressure (mmHg)87.1 ± 9.273.0 ± 10.571.9 ± 10.8
Glucose (mg/dl)102 ± 2491 ± 18104 ± 33*
Metabolic syndrome261 (32.6)267 (32.1)766 (73.8)*
Metabolic factors, median§2.0 (2)2.0 (2)3.0 (2)*
Diabetes76 (9.5)55 (6.6)225 (21.7)*
Use of gout medication13 (1.6)7 (0.8)11 (1.1)
Use of lipid-lowering drugs25 (3.1)64 (7.7)122 (11.9)*
  • Data are means ± SD or n (%) unless otherwise indicated.

  • * P < 0.001;

  • P < 0.05 for comparison between severely obese subjects and control subjects from Utah.

  • Definition according to the scientific statement from the American Heart Association and the National Heart, Lung, and Blood Institute. Three of the following five parameters had to be present: elevated waist circumference (≥102 cm in men and ≥88 cm in women); elevated triglycerides (≥150 mg/dl [1.7 mmol/l]) or receiving drug treatment for elevated triglycerides; reduced HDL cholesterol (<40 mg/dl [1.03 mmol/l] in men and <50 mg/dl [1.3 mmol/l] in women) or receiving drug treatment for reduced HDL cholesterol; hypertension (≥130 mmHg systolic blood pressure or ≥85 mmHg diastolic blood pressure) or receiving antihypertensive drug treatment in a patient with a history of hypertension; or elevated fasting glucose (≥100 mg/dl) or receiving drug treatment for elevated glucose.

  • § Metabolic factors: average number of factors considered in the definition of metabolic syndrome (see preceding footnote), measured as median (interquartile range). MAF, minor allele frequency.